Guggenheim Initiates Buy on Cullinan Therapeutics with $30 Target
Guggenheim starts coverage on Cullinan Therapeutics with a Buy rating, citing promising Phase 1 data for T-cell engagers in autoimmune diseases and AML.
NOTRELOAD AI
FDA Requests More Data for Joenja in Younger Children with APDS
Pharming (PHAR) receives FDA Complete Response Letter for Joenja (leniolisib) in children aged 4-11 with APDS. Additional data needed on dosing and testing methods.
Guggenheim Gives Avalo Therapeutics a Buy Rating on AVTX-009
Guggenheim starts coverage of Avalo Therapeutics with a Buy rating, highlighting AVTX-009 as a promising IL-1beta treatment for Hidradenitis suppurativa (HS) and $2.1B peak sales potential.
William Blair Upgrades Palantir Ahead of Earnings
Analyst Louie DiPalma upgrades Palantir to Outperform, citing continued momentum, strong government support, and potential growth in AI-related markets.
Devon Energy & Coterra Merge to Create Shale Giant
Devon Energy and Coterra announce $58B merger creating premier shale operator with strong Delaware Basin position and $1B annual synergies.
Disney Beats Q1 Expectations But Warns of Slowdown Ahead
Disney's record theme park sales drove strong Q1 results, but the company forecasts modest growth amid international tourism challenges and rising sports costs.